Szabó B, Tóth F D, Kiss J, Váczi L, Kiss A, Rák K
Institute of Microbiology, University Medical School, Debrecen, Hungary.
Acta Microbiol Hung. 1988;35(3):295-300.
Blood plasma interferon (IFN) of patients with acute myeloid (AML) and chronic granulocytic (CGL) and with acute and chronic lymphoid leukaemia (ALL and CLL) was measured by bioassay and characterized by neutralization with anti-human-IFN-alpha treatment. Elevated IFN-alpha level (60-125 IU/ml) was found in the quiescent phase of CGL as compared to the control samples (15 +/- 10 IU/ml). No significant differences could be found between plasma IFN of patients suffering from the blastic crisis of CGL and control persons. Analogous results were obtained in experiments with plasmas of AML patients, regardless the stage of the disease. Elevated IFN-alpha production (60-100 IU/ml) was found in patients being in the remission phase of T-cell ALL but only in one case in the progressive phase of the disease. No significant elevation of plasma IFN level was demonstrated in patients with O-cell ALL and B-cell CLL, as compared to the control samples.
通过生物测定法对急性髓性白血病（AML）、慢性粒细胞白血病（CGL）以及急性和慢性淋巴细胞白血病（ALL和CLL）患者的血浆干扰素（IFN）进行了测量，并通过抗人IFN-α处理进行中和来对其进行表征。与对照样本（15±10 IU/ml）相比，在CGL的静止期发现IFN-α水平升高（60 - 125 IU/ml）。在CGL急变期患者的血浆IFN与对照人群之间未发现显著差异。在AML患者血浆的实验中也获得了类似结果，无论疾病处于何种阶段。在T细胞ALL缓解期的患者中发现IFN-α产生升高（60 - 100 IU/ml），但在疾病进展期仅1例出现这种情况。与对照样本相比，O细胞ALL和B细胞CLL患者的血浆IFN水平未显示出显著升高。
